Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and reduce the risk of blood clots. Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. It is taken by mouth.
Read the full article on WikipediaPrevention of recurrent venous thromboembolism Clinical criteria: Treatment Phase: Continuing treatment Patient must have a history of venous thromboembolism.
Chronic stable atherosclerotic disease Clinical criteria: Treatment Phase: Continuing treatment Patient must have received PBS-subsidised treatment with this drug for this condition, AND The treatment must be in combination with aspirin, but not with any other anti-platelet therapy.
Deep vein thrombosis Clinical criteria: Treatment Phase: Continuing treatment The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND Patient must have confirmed acute symptomatic deep vein thrombosis, AND Patient must not have symptomatic pulmonary embolism.
Pulmonary embolism Clinical criteria: Treatment Phase: Continuing treatment The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND Patient must have confirmed acute symptomatic pulmonary embolism.
Prevention of stroke or systemic embolism Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND Patient must have non-valvular atrial fibrillation, AND Patient must have one or more risk factors for developing stroke or systemic embolism. Risk factors for developing stroke or systemic ischaemic embolism are: (i) Prior stroke (ischaemic or unknown type), transient ischaemic attack or non-central nervous system (CNS) systemic embolism; (ii) age 75 years or older; (iii) hypertension; (iv) diabetes mellitus; (v) heart failure and/or left ventricular ejection fraction 35% or less.
Prevention of venous thromboembolism Clinical criteria: Treatment criteria: Patient must be undergoing total hip replacement. Patient must require up to 30 days supply to complete a course of treatment.
“Rivaroxaban inhibits both free and bound Factor Xa in the prothrombinase complex. It is a selective direct factor Xa inhibitor with an onset of action of 2.5 to 4 hours. Inhibition of Factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated Factor II), and no effects on platelets have been demonstrated. It allows predictable anticoagulation and dose adjustments and routine coagulation monitoring; dietary restrictions are not needed.”
“5–9 hours in healthy subjects aged 20 to 45”
Working under the parallel aged-care framework? Aged-care equivalent →